Literature DB >> 30943512

Treatment Options for Hypopharyngeal Cancer.

Hans E Eckel1, Patrick J Bradley2.   

Abstract

Patients with hypopharyngeal cancer are difficult to treat because they typically present with advanced disease, poor general health status and severe nutritional problems. Currently, treatment options for previously untreated and newly diagnosed hypopharyngeal cancer patients include surgery of the primary tumour and lymph nodes metastasis, radiotherapy, systemic medical treatment, including traditional chemotherapy and immunotherapy. Currently, a multimodal treatment approach is preferred using surgery, radiotherapy and systemic therapy with curative intent and best supportive care in patients considered unfit for curative treatment or patients presenting with distant metastatic spread. More detailed topics regarding the choice of treatment include biological and immunological host factors and their use for defining individualised cancer care, integration of novel therapies, integration of patient autonomy into clinical reasoning and dealing with patients' trade-offs between oncological outcome and individual quality of life, local availability of diagnostic therapeutic procedures and volume-outcome relationships for head and neck cancer surgery, radiotherapy and specialised supportive care. They also include considerations regarding potential delay between diagnosis and treatment, and between different treatment modalities within the frame of multimodal therapy. To date only one randomised trial comparing surgical versus non-surgical approaches has been published. Most randomised trials dealing with hypopharyngeal cancer compare different chemo- and radiotherapy regimen, but do not compare with a surgical approach. On the other hand, most studies on the results of surgery are best considered to be of low-quality case series. At the same time, many of the chemotherapy and radiation oncology studies in head and neck cancer include patients with different primary sites, where hypopharyngeal cancer patients when included usually account for a minority of the study population. Therefore, choosing the best treatment for an individual patient with hypopharyngeal cancer relies on personal experience and local expertise of the multidisciplinary team involved in the therapeutic process.
© 2019 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30943512     DOI: 10.1159/000492308

Source DB:  PubMed          Journal:  Adv Otorhinolaryngol        ISSN: 0065-3071


  8 in total

1.  LncRNA MALAT1 inhibits the proliferation and invasiveness of laryngeal squamous cell carcinoma Hep-2 cells by modulating miR-362-3p.

Authors:  Baotong Xie; Zhaohua Wang; Tao Li; Junfang Xue; Chunming Zhang
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

2.  Biomarker discovery for practice of precision medicine in hypopharyngeal cancer: a theranostic study on response prediction of the key therapeutic agents.

Authors:  Yumiko Kawata-Shimamura; Hidetaka Eguchi; Reika Kawabata-Iwakawa; Mitsuhiko Nakahira; Yasushi Okazaki; Tetsuya Yoda; Reidar Grénman; Masashi Sugasawa; Masahiko Nishiyama
Journal:  BMC Cancer       Date:  2022-07-16       Impact factor: 4.638

3.  The role of NBI with flexible video-endoscope in the follow-up of head and neck cancer patients: a prospective study.

Authors:  Francesca Boscolo Nata; Nicoletta Gardenal; Fabiola Giudici; Giancarlo Tirelli
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-07-25       Impact factor: 2.503

4.  Overexpression of microRNA-107 suppressed proliferation, migration, invasion, and the PI3K/Akt signaling pathway and induced apoptosis by targeting Nin one binding (NOB1) protein in a hypopharyngeal squamous cell carcinoma cell line (FaDu).

Authors:  Xin Gao; Xinlong Fan; Wei Zeng; Jiwang Liang; Nan Guo; Xiao Yang; Yuejiao Zhao
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

5.  Positron emission tomography and magnetic resonance imaging combined with computed tomography in tumor volume delineation: A case report.

Authors:  Qi-Ping Zhou; Yu-Hua Zhao; Lei Gao
Journal:  World J Clin Cases       Date:  2022-01-07       Impact factor: 1.337

6.  Second Primary Malignancy in Patients with Hypopharyngeal Carcinoma: A SEER-Based Study.

Authors:  Liqing Guo; Yanpeng Fu; Chunyu Miao; Shuhong Wu; Yaqiong Zhu; Yuehui Liu
Journal:  Int J Gen Med       Date:  2021-11-25

7.  Influence of Tumor Site on Survival in Young Patients with Head and Neck Squamous Cell Carcinoma.

Authors:  Claudius Steffen; Iris Piwonski; Max Heiland; Carmen Stromberger; Grzegorz Kofla; Christian Doll; Annekatrin Coordes; Benedicta Beck-Broichsitter
Journal:  Curr Oncol       Date:  2022-02-10       Impact factor: 3.677

8.  RBM24 Mediates Lymph Node Metastasis and Epithelial-Mesenchymal Transition in Human Hypopharyngeal Squamous Cell Carcinoma by Regulating Twist1.

Authors:  Yuhong Liu; Min Pan; Tao Lu; Yanshi Li; Dan Yu; Zhihai Wang; Guohua Hu
Journal:  J Oncol       Date:  2022-09-29       Impact factor: 4.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.